Craft

Lundbeck

Stock Price

KR32.4

2024-06-07

Market Capitalization

KR35.7 B

2024-06-07

Revenue

KR19.9 B

FY, 2023

Lundbeck Summary

Company Summary

Overview
H. Lundbeck is a pharmaceutical company specializing in brain diseases. It is engaged in research, development, manufacturing, and commercialization of pharmaceuticals.
Type
Public
Status
Active
Founded
1915
HQ
København, DK | view all locations
Website
https://www.lundbeck.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Charl van Zyl
  • Joerg Hornstein

    Joerg Hornstein, CFO & Executive Vice President, Corporate Functions

  • Lars Bang

    Lars Bang, Executive Vice President, Product Development & Supply

    • Dianne Hol

      Dianne Hol, Executive Vice President, People & Organization

      Operating MetricsView all

      Trademarks

      2.7K

      May, 2024

      Countries

      100

      May, 2024

      Trademark Applications

      212

      May, 2024

      LocationsView all

      48 locations detected

      • København HQ

        Denmark

        Ottiliavej 9

      • Deerfield, IL

        United States

        6 Parkway N

      • Buenos Aires, Cdad. Autónoma de Buenos Aires

        Argentina

        Heredia 553

      • North Ryde, NSW

        Australia

        Innovation Rd

      • Wien, Wien

        Austria

        Spaces Square One Leopold Ungar Platz 2

      • Bruxelles, Bruxelles

        Belgium

        Stephanie Square Centre Louizalaan/Avenue Louise 65, Box 11

      and 42 others

      Lundbeck Financials

      Summary Financials

      Revenue (Q1, 2024)
      kr5.3B
      Gross profit (Q1, 2024)
      kr4.7B
      Net income (Q1, 2024)
      kr1.0B
      Cash (Q1, 2024)
      kr5.1B
      EBIT (Q1, 2024)
      kr1.3B
      Enterprise value
      $34.7B

      Footer menu